Stéphane Bigler | EPFL Graph Search

À propos de ce résultat

Cette page est générée automatiquement et peut contenir des informations qui ne sont pas correctes, complètes, à jour ou pertinentes par rapport à votre recherche. Il en va de même pour toutes les autres pages de ce site. Veillez à vérifier les informations auprès des sources officielles de l'EPFL.

Comparison Between the eyeWatch Device and the Ahmed Valve in Refractory Glaucoma

Stéphane Bigler, André Mermoud, Sylvain Roy, Nikolaos Stergiopulos, Constantinos Stergiopulos, Adan Villamarin

Purpose: To assess the efficacy and safety of a glaucoma procedure to control intraocular pressure (IOP) using the adjustable eyeWatch glaucoma drainage device compared with Ahmed glaucoma valve (AGV) in refractory glaucoma. Patients and Methods: Monocentric, retrospective, comparative clinical trial. Patients suffering from refractory glaucoma after failed surgeries and requiring a further glaucoma procedure including an aqueous shunt were enrolled in this study. The first group AGV included patients with an AGV. The second group eW-B included patients receiving an eyeWatch used in connection with a Baerveldt glaucoma implant. The primary outcome was the success rate, defined as an IOP 20% from baseline, and IOP >= 5 mm Hg. Secondary outcomes were mean IOP, number of antiglaucoma medications, visual acuity, number and type of complications. Results: Twenty-one patients were included. The mean follow-up time was 13.2 +/- 3.4 months. Mean IOP decreased from 24.8 +/- 9.0 mm Hg before surgery to 13.8 +/- 3.6 mm Hg at 12 months for group AGV, and 27.3 +/- 7.0 to 12.8 +/- 2.4 mm Hg for group eW-B, respectively (P

LIPPINCOTT WILLIAMS & WILKINS2020

Initial Clinical Results of the eyeWatch: a New Adjustable Glaucoma Drainage Device Used in Refractory Glaucoma Surgery

Stéphane Bigler, André Mermoud, Sylvain Roy, Nikolaos Stergiopulos, Constantinos Stergiopulos, Adan Villamarin

Precis: In this study, we report clinical results after implantation of an adjustable glaucoma drainage device. The intraocular pressure (IOP) profile was efficiently controlled postoperatively as the resistance to aqueous humor outflow was finely adjusted. Purpose: The main purpose of this study was to evaluate the safety and efficacy of the new adjustable glaucoma drainage device eyeWatch used in conjunction with a Baerveldt glaucoma implant in refractory glaucoma. Patients and Methods: This was a multicentric, prospective, noncomparative clinical trial. Patients older than 18 years of age suffering from refractory glaucoma after failed surgeries, with IOP of >= 20 mm Hg, in whom a further glaucoma procedure using an aqueous shunt was planned, were enrolled in this study. The primary outcome was the success rate, defined as an IOP 20% from baseline, IOP >= 6 mm Hg. Secondary outcomes were mean IOP, visual acuity, number of antiglaucoma medications, number, and type of complications. Results: Fifteen patients were included. The mean follow-up time was 15.6 +/- 3.5 months. The mean baseline IOP decreased from 26.2 +/- 6.8 mm Hg before surgery to 11.9 +/- 2.8 mm Hg at 12 months (P

LIPPINCOTT WILLIAMS & WILKINS2019

Apparatus and methods for treating excess intraocular fluid

Stéphane Bigler, Nikolaos Stergiopulos

An ocular drainage system is provided for treating diseases that produce elevated intraocular pressures, such as glaucoma, wherein the system includes an implantable device and an external control unit, the implantable device includes a non-invasively adjustable valve featuring at least one deformable tube and a disk rotatably mounted within a housing, such that rotation of the disk using the external control unit causes the disk to apply a selected amount of compression to the deformable tube, thereby adjusting the fluidic resistance of the deformable tube and regulating the intraocular pressure.

2017